ExpreS2ion and Attana have signed a Development and Supply Agreement

Report this content

Hørsholm, Denmark, September 24, 2020 – ExpreS2ion Biotech Holding AB hereby announces that its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") and the biotech tools company Attana AB (“Attana”) have today signed a heads of terms agreement regarding the development and supply of novel ExpreS2ion proteins to Attana. The first target protein will be the ExpreS2ion-produced SARS-CoV-2 spike and receptor-binding-domain (RBD) antigen used in ExpreS2ion’s COVID-19 vaccine program. Attana will now be able to offer customers utilising its AVA diagnostic platform this and other novel ExpreS2ion proteins. The parties are not disclosing the commercial terms of the agreement.

In early June, ExpreS2ion announced that the capsid virus-like particle (cVLP) COVID-19 vaccine being developed by ExpreS2ion and its joint venture AdaptVac demonstrated excellent COVID-19 immunization with a very high level of SARS-CoV-2 virus neutralization in a mice model, thus reaching an important pre-clinical milestone ahead of schedule.

Attana assisted in the preclinical development of the vaccine by performing various studies on ExpreS2ion’s novel antigen in its AVA diagnostic platform. The parties were able to confirm key characteristics such as the degree of non-specific immune system response, relative concentration of specific antibodies, quality of specific antibodies and relative concentration of SARS-CoV-2 IgG antibodies.

Based on this positive outcome, ExpreS2ion and Attana have now agreed on commercial terms of a development and supply agreement that will enable other Attana AVA customers to use this and other ExpreS2ion-produced proteins in their projects.

ExpreS2ion’s CEO Bent Frandsen comments:

“It is promising that we are able to increase the availability and usability of our SARS-CoV-2 antigen, and other ExpreS2ion-produced proteins, by signing this agreement with Attana. It will hopefully increase the attractiveness of both companies in the diagnostic sector. Based on the successful utilisation of the AVA platform in our COVID-19 vaccine program, it is also of interest to us to deepen our relationship with Attana considering our ambition to further broaden and advance our project pipeline.”

Attana’s CEO Teodor Aastrup comments:

“The Attana Virus Analytics (AVA) platform, in combination with the novel SARS-CoV-2 antigen developed by ExpreS2ion, has been shown to provide valuable insights into the immunological response to COVID-19. Having worked together with ExpreS2ion during the past few months, we are happy to today announce this agreement and look forward to also jointly developing additional novel proteins to broaden the application areas of our AVA platform.”

About Attana

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in-vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se


For further information about ExpreS2ion, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869

This press release constitutes information that ExpreS2ion Biotech Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company’s news distributor, Cision, at the publication of this press release.

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.